This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Spain’s Hospital Universitario 12 de Octubre researchers, along with the Josep Carreras Leukaemia Research Institute, have developed a new cell therapy based on STAb cells to treat a type of leukaemia. The post Hospital Universitario and Josep Carreras develop cell therapy for leukaemia appeared first on Pharmaceutical Technology.
With the results in hand, the developers of the therapy – from the Netherlands Cancer Institute and Norway’s National Center for Cancer Immune Therapy – say they now intend to file for regulatory approvals in Europe before the end of the year, without a commercial partner “to try to ensure that it remains affordable.”
More specifically, CAR-T cell therapy engineers a patient’s own immune cells (T-cells) to detect, target, and destroy cancer cells. After initial chemotherapy, up to 45% of patients with DLBCL will require a second line treatment, which often involves high-dose chemotherapy and a stem cell transplant.
A human CD40 agonistic antibody targeting CD40, mitazalimab kickstarts the cancer-immunity cycle by priming and activating tumour-specific T cells. Targeting CD40 with mitazalimab has the potential to augment responses to chemotherapy. A median duration of response of 8.7 months was also reported.
In May, a Phase 2 study started, comparing Kaiku’s electronic patient-reported outcome (ePRO) approach to evaluating immune-related adverse events to the standard model of care in cancer patients treated with checkpoint inhibitor drugs, with results due towards the end of 2023 or in early 2024.
The idea of cancer vaccines is not new, but Dr Victoria Kunene, consultant medical oncologist at Queen Elizabeth Hospital Birmingham, UK, is leading the charge in their latest iteration: personalised preventative and therapeutic mRNA vaccines against colorectal cancer. Of course, we’ve also had the advent of immune checkpoint inhibitors.
Sanjay Prasad MD has been a consultant in cardiology and cardiovascular magnetic resonance at the Royal Brompton Hospital since 2003 and is also Professor of Cardiomyopathy at Imperial College, London. In contrast, in drug-related causes, especially chemotherapy, patients were generally aged 50–60 years. Reference Lota As et al.
“If we work closely with government stakeholders and possibly collaborate on developing innovative access schemes for rare diseases, cancers, immune and inflammatory disorders, we can encourage greater participation by established biopharmas and stimulate the growth of entrepreneurial local companies in the region.”. million in 2030.
4,5 Polypharmacy – daily use of five or more drugs – is common in these patients and increases the risk of DRPs, which can result in adverse outcomes such as postoperative complications, chemotherapy toxicities and functional decline. 10,11 This can be due to side effects of chemotherapy or the addition of certain supportive care medications.
Administered as an intravenous infusion, it works by encouraging healthy immune cells in the body to destroy the cancer cells. By bringing these cells together, the patient’s own immune system is activated and kills the cancer cell and so chemotherapy is not required. ‘By
The goal for cancer vaccines is straightforward: to harness what has been achieved for infectious diseases and their antigens to focus the immune system on eradicating cancer cells. Moving forward, exploring the factors contributing to variability in patients’ immune responses will be critical.
chimeric antigen receptor T-cell (CAR-T) therapy is a form of personalised immunotherapy that utilises the patient’s own immune which are modified to destroy cancer cells. The post NICE approves Yescarta for relapsed/remitted lymphomas appeared first on Hospital Pharmacy Europe.
Mitazalimab is a human CD40 agonistic antibody targeting CD40 and which kickstarts the cancer-immunity cycle by priming and activating tumour-specific T cells. Targeting CD40 with MM has the potential to augment responses to chemotherapy.
Roberta di Blasi MD PhD is a haematologist at Saint Louis Hospital in Paris where she is a specialist in CAR-T cell therapy for lymphoma. The unit has 16 beds and treats patients with chemotherapy and CAR-T cell therapy. How is CAR-T authorised and used in your hospital? Could you provide a brief summary of CAR-T therapy?
After focusing on bone marrow transplantation as part of her specialist medical training, Dr Sara Ghorashian was curious about developing a more precise tool to utilise the immune system to fight cancer. These patients often reach the ceiling for toxicity in terms of chemotherapy and radiotherapy in the context of a bone marrow transplant.
This test helps healthcare professionals diagnose a variety of diseases, such as kidney disease, liver damage, and autoimmune disorders, and provides information about one’s immune function. g/dL and may be associated with infections, certain cancers, or immune disorders. It occurs when the immune system is activated.
Amivantamab is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Vitamin D supplementation increased 25-hydroxyvitamin-D levels significantly, suggesting a potential role in enhancing chemotherapy effectiveness. The study's findings support further research with larger samples to explore vitamin D's impact on chemotherapy and breast cancer remission likelihood.
Sanofi Reports P-IIIb Trial (HARMONIE) Results of Nirsevimab for the Prevention of Hospitalizations due to RSV-Related LRTD Date: May 12, 2023 | Tags: Sanofi, Nirsevimab, RSV-Related LRTD, Clinical Trial, P-IIIb, HARMONIE Trial G1 Therapeutics Presents Preliminary Results from P-II Trial of Trilaciclib for Triple-Negative Breast Cancer at ESMO 2023 (..)
Antihistamines work by blocking the effects of histamine , a chemical released by your body’s immune system. Antiemetics may also reduce radiation-associated or chemotherapy-induced nausea resulting from cancer treatment. Antihistamines When you think about antihistamines , allergy medications may come to mind.
These medications all tell immune system cells to produce more anti-inflammatory mediators and less inflammatory products. Injectable formulations of methotrexate are utilized as chemotherapy against various cancers. Glucocorticoid names include prednisone , prednisolone , triamcinolone, and dexamethasone.
Benmelstobart (TQB2450; Chia Tai Tianqing Pharmaceutical Group Co, Ltd) in combination with chemotherapy followed by sequential combination with anlotinib (Catequentinib; Advenchen Laboratories) led to significant improvements in progression-free survival (PFS), with a manageable safety profile. months versus 7.79 months with tislelizumab.
1 Biomarker testing is relatively new in the treatment landscape for NSCLC but has proven incredibly important for personalizing patient care, transforming from a generic chemotherapy approach to a highly personalized, genomically driven treatment strategy. For advanced disease, chemotherapy was the standard.
Transportation barriers, as a health-related social need, significantly impact FN rates in chemotherapy patients. Febrile neutropenia (FN) remains a serious and common complication of chemotherapy. A 67% FN rate difference between pegfilgrastim and filgrastim was observed in patients with transportation barriers.
Secondary outcomes included rates of specialist referrals and asthma-related emergency department (ED) visits or hospitalizations. Asthma exacerbations requiring acute care were rare but notable: 1 patient visited the ED, and 3 were hospitalized, all of whom were in the track 2 group.
Wick, MBA, RPh, FASCP Key Takeaways Pharmacists can address SDOH by providing patient-centered care, promoting immunizations, and offering point-of-care testing to improve health outcomes. Offering and promoting immunizations and point-of-care testing are 2 proven ways to address SDOH.
Mok : Right now, we have a lot of chemotherapy being used, but there are many more novel treatments being studied, especially in earlier lines of treatment. Bispecifics are moving up in the lymphoma space, and these newer therapies may have some synergistic effects with chemotherapy. REFERENCES 1. Updated August 18, 2021.
For example, CPAs are especially impactful in managing chronic conditions such as diabetes, heart failure, and rheumatoid arthritis, where pharmacist intervention has been shown to improve outcomes and reduce hospitalizations. Subscribe Now!
The convenience of once-daily dosing and a rapid IV bolus administration may offer workflow efficiencies in hospital or surgical settings, where minimizing polypharmacy and streamlining medication administration are important goals.
Datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc) received FDA approval for treatment of adults with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy.
Approximately 40% to 80% of patients with cancer who are assigned female at birth face possible infertility as a result of their cancer treatments, such as chemotherapy, radiation, and surgery. An additional 15% to 30% of cancer survivors who are assigned male at birth also face infertility as a result of chemotherapy.
Conclusions We demonstrated the feasibility of leveraging a complex EHR data source from an integrated health system to study the impact of dose modifications on clinical outcomes for self-administered chemotherapy. Nearly half of the patients with CML on imatinib experienced dosage modifications in this study.
Have you observed these immune-related toxicities in your practice, and if so, how are they being managed? Blood cancer patients are usually at higher risk due to prior chemotherapy, and maybe we don’t need the same kind of prophylactic medications for solid tumor patients. All patients should have immunotherapy first.
Additionally, patients may have received prior chemotherapy for advanced disease. Additionally, taletrectinib was granted priority review, breakthrough designation, and orphan drug designation for this indication. For both trials, the major efficacy outcomes were confirmed overall response rate (cORR) and duration of response (DOR).
Yes, we currently have antibody-drug conjugates that are conjugated to a cytotoxic chemotherapy. So there’s things in the pipeline that are being developed with novel conjugated agents, such as radiopharmaceuticals, immune-activating agents like STING agents, PROTACs. Unfortunately, these drugs are quite toxic.
The hospitals and the payment plans would not use your generic drug if you weren’t therapeutically equivalent—we would exclude you,” Soefje said. Historically, CMS would stack all multisource generic 505(b)(2) drugs under the same J-code, Soefje explained. That has changed based upon the [recent] CMS ruling.”
At Children’s Hospital of Philadelphia (CHOP), eligible patients can access 12 advanced therapeutics and 8 more in the pipeline. Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2.
This entails an increased risk of developing secondary diseases, such as type 2 diabetes and cardiovascular diseases,” Wile Balkhed, PhD student at Linköping University and resident physician at Linköping University Hospital, said in a news release.
A perioperative approach that includes both neoadjuvant and adjuvant immune checkpoint inhibition with pembrolizumab significantly improves disease outcomes for patients with early-stage non-small-cell lung cancer (NSCLC), according to the findings of a trial by an international research group.
A Phase III trial from Shanghai Henlius Biotech is the first study to suggest that the programmed cell death (PD) 1 receptor immune checkpoint inhibitor Hansizhuang (serplulimab) plus chemotherapy can markedly improve survival for extensive-stage small cell lung cancer (ES-SCLC) patients. A follow-up after 12.3 months).
Because biologics and biosimilar products are large and complex proteins, there is a higher risk of a patient’s body identifying them as an “outside source” and mounting an immune response to them. Our bodies don't like foreign sources. They like the things that it creates itself.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content